GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ —
-
NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations granted by 12 regulatory agencies and emergency use listing from the WHO
-
Additional filings for authorization under review, including in the United States
-
Initiated vaccine shipments globally, with doses administered in the European Union, Australia,
Source link
